Ad
KDMN Quote Trading Chart Kadmon Holdings Inc.
home / stock / kdmn / kdmn quote
Quote | Kadmon Holdings Inc. (NASDAQ:KDMN)
| Last: | $9.50 |
|---|---|
| Change Percent: | 0.21% |
| Open: | $9.49 |
| Close: | $9.50 |
| High: | $9.5 |
| Low: | $9.48 |
| Volume: | 10,206,411 |
| Last Trade Date Time: | 11/08/2021 04:56:02 pm |
Quotes are delayed by 15 to 20 minutes.
KDMN Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $9.5 | $9.49 | $9.5 | $9.5 | $9.48 | 10,206,411 | 11-08-2021 |
| $9.48 | $9.48 | $9.48 | $9.49 | $9.47 | 6,750,178 | 11-05-2021 |
| $9.47 | $9.47 | $9.47 | $9.48 | $9.47 | 4,693,124 | 11-04-2021 |
| $9.48 | $9.48 | $9.48 | $9.48 | $9.46 | 2,935,175 | 11-03-2021 |
| $9.46 | $9.45 | $9.46 | $9.48 | $9.45 | 2,602,736 | 11-02-2021 |
| $9.46 | $9.45 | $9.46 | $9.465 | $9.45 | 4,918,198 | 11-01-2021 |
| $9.45 | $9.44 | $9.45 | $9.46 | $9.44 | 3,433,748 | 10-29-2021 |
| $9.46 | $9.43 | $9.46 | $9.46 | $9.42 | 4,145,545 | 10-28-2021 |
| $9.42 | $9.43 | $9.42 | $9.44 | $9.41 | 3,807,375 | 10-27-2021 |
| $9.42 | $9.43 | $9.42 | $9.44 | $9.42 | 6,204,839 | 10-26-2021 |
| $9.42 | $9.4 | $9.42 | $9.46 | $9.4 | 13,292,962 | 10-25-2021 |
| $9.405 | $9.405 | $9.405 | $9.41 | $9.39 | 17,037,625 | 10-22-2021 |
| $9.42 | $9.35 | $9.42 | $9.42 | $9.34 | 98,706,222 | 10-21-2021 |
| $8.6 | $8.57 | $8.6 | $8.675 | $8.535 | 5,601,175 | 10-20-2021 |
| $8.54 | $8.62 | $8.54 | $8.7 | $8.52 | 5,565,806 | 10-19-2021 |
| $8.59 | $8.75 | $8.59 | $8.75 | $8.555 | 5,297,505 | 10-18-2021 |
| $8.73 | $8.93 | $8.73 | $8.94 | $8.73 | 2,634,627 | 10-15-2021 |
| $8.87 | $8.96 | $8.87 | $9.01 | $8.84 | 2,585,910 | 10-14-2021 |
| $8.96 | $8.87 | $8.96 | $8.97 | $8.84 | 1,218,475 | 10-13-2021 |
| $8.9 | $8.95 | $8.9 | $9.01 | $8.87 | 2,125,224 | 10-12-2021 |
News, Short Squeeze, Breakout and More Instantly...
Kadmon Holdings Inc. Company Name:
KDMN Stock Symbol:
NASDAQ Market:
0.21% G/L:
$9.50 Last:
10,206,411 Volume:
$9.49 Open:
$9.50 Close:
Kadmon Holdings Inc. Website:
Ad
-
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch...
Important Investor News Alert (NASDAQ: CVKD)
-
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per ev...